Weikang Pharmaceutical released its 2026 interim report. Total operating revenue was 126 million yuan, net profit attributable to the parent company was negative 22.2556 million yuan, and net cash flow from operating activities was negative 24.6241 million yuan, a decrease of 69.0291 million yuan compared with the same period last year, down 155.45 percent year on year. The company's asset-liability ratio was 28.89 percent, gross margin was 40.24 percent, return on equity was negative 2.51 percent, and diluted earnings per share was negative 0.15 yuan. The number of shareholders was 8,106, and the top ten shareholders held 76.63 percent of the total share capital.
Wecome Pharmaceutical Co LtdNet loss of 22.2556 million yuan and negative operating cash flow in interim report.
